Cover Image
市場調查報告書

肽治療藥的全球市場 (2016∼2020年)

Global Peptide Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317311
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
肽治療藥的全球市場 (2016∼2020年) Global Peptide Therapeutics Market 2016-2020
出版日期: 2016年03月04日 內容資訊: 英文 81 Pages
簡介

肽為有機化合物之一,透過肽結合以科學性結合的氨基酸構成。在生物活性成分中尤其是潛力最高的物質,用於促進、控制、維持人的生理過程。可是,由於肽非常不穩定,無法通過細胞膜,要作為治療藥使用通常有困難。還有合成過程的困難和成本高也得解決。跨越那樣的困難,現在有80種以上的產品上市,使用於慢性疾病的治療。全球肽治療藥市場,預計2016年∼2020年的期間中,年複合成長率 (CAGR) 為7.92%。

本報告提供全球肽治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 肽的概要

  • 肽的合成方法
  • 肽的最佳化
  • 肽的穩定化

第6章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第7章 各給藥途徑的市場區隔

  • 非口服給藥
  • 口服給藥
  • 經肺給藥
  • 經粘膜給藥

第8章 各類藥物的市場區隔

  • 生長抑制素
  • 增壓素
  • 抑鈣素
  • LHRH (黃體激素 (LH) 放出荷爾蒙)
  • 升糖素與其類似體
  • 胰島素
  • 其他

第9章 各合成技術的市場區隔

  • 液相肽合成
  • 固相肽合成
  • 混合合成

第10章 地區區分

  • 全球肽治療藥市場:各地區的詳細趨勢 (2015∼2020年)
  • 南北美洲市場
  • 歐洲、中東、非洲各國 (EMEA) 市場
  • 亞太地區市場

第11章 推動市場要素

  • 患者人口的增加
  • 肽合成技術的進步
  • 有未來潛力的開發中產品
  • 醫療上的未滿足需求
  • 醫療費用支出的增加

第12章 推動因素的影響力

第13章 市場課題

  • 治療費高
  • 副作用
  • 嚴格的法規的遵守
  • 市場競爭加劇

第14章 推動因素、課題的影響力

第15章 市場趨勢

  • 廣受歡迎
  • 關心轉移到未開發市場
  • 受託製造
  • 一般認知度的上升

第16章 供應商環境

  • 競爭方案
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • 武田藥品工業
  • Teva Pharmaceuticals
  • 其他卓越供應商

第17章 附錄

  • 簡稱集

第18章 關於Technavio

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR8630

About Peptide Therapeutics

Peptides are organic compounds that are composed of amino acids linked chemically by peptide bonds. They are the most potent biologically active substances found in nature and are used to trigger, control, and maintain an individual's physiological processes. However, using peptides as therapeutic agents was always difficult as they are quite instable and cannot pass through cellular membranes. They also require a specific technology to tackle extensive and challenging steps in their synthesis. Over 80 peptides are marketed by companies that explore the probabilities of designing and engineering peptides that can overcome their natural limits. They can be introduced as a treatment for chronic indications.

Technavio's analysts forecast the global peptide therapeutics market to grow at a CAGR of 7.92% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global peptide therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of prescription and generic drugs used to treat diseases.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Peptide Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceuticals

Other Prominent Vendors

  • AbbVie
  • Advanced Accelerator Applications
  • Akashi Therapeutics
  • Amgen
  • Anthera Pharmaceuticals
  • AstraZeneca
  • Bachem
  • Bristol-Myers Squibb
  • Cardiorentis
  • Corden Pharma International
  • Debiopharm
  • Derma Sciences
  • GlaxoSmithKline
  • Hanmi Pharmaceutical
  • Insmed
  • Ipsen
  • Johnson & Johnson
  • Lonza
  • Mallinckrodt
  • MolMed
  • Merck
  • Novartis
  • Nymox Pharmaceutical
  • Par Pharmaceuticals
  • PeptiDream
  • Polypeptide Group
  • Radius Health
  • Repligen
  • Roche
  • SciClone
  • Shire
  • The Medicines Company
  • Transition Therapeutics
  • X-Gen Pharmaceuticals
  • Zealand Pharma
  • Zydus Cadila

Market driver

  • Increase in patient population
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Shifting focus toward untapped markets
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview of peptides

  • Peptide synthesis
  • Optimization of peptides
  • Stabilization of peptides
  • PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation based on route of administration

  • Parenteral
  • Oral
  • Pulmonary
  • Mucosal

PART 08: Market segmentation by drug class

  • Somatostatins
  • Vasopressin
  • Calcitonins
  • Luteinizing hormone (LH)-releasing hormone (LHRH)
  • Glucagon and analogs
  • Insulins
  • Other

PART 09: Market segmentation by synthesis technology

  • Liquid-phase peptide synthesis
  • Solid-phase peptide synthesis
  • Hybrid peptide synthesis

PART 10: Geographical segmentation

  • Global peptide therapeutics market segmentation by geography 2015-2020
  • Peptide therapeutics market in Americas
  • Peptide therapeutics market in EMEA
  • Peptide therapeutics market in APAC

PART 11: Market drivers

  • Increase in patient population
  • Advances in peptide synthesis technology
  • Promising pipeline
  • Unmet medical needs
  • Increase in healthcare spending

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of therapy
  • Adverse side effects
  • Stringent regulatory compliances
  • Intense market competition

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Growing popularity
  • Shifting focus toward untapped markets
  • Contract manufacturing
  • Increase in public awareness

PART 16: Vendor landscape

  • Competitive scenario
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceuticals
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: SWOT analysis: Peptide therapeutics
  • Exhibit 03: Steps involved in peptide synthesis
  • Exhibit 04: Optimization of peptide synthesis
  • Exhibit 05: Methods used to stabilize peptides
  • Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions)
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Global peptide therapeutics market segmentation based on route of administration
  • Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015
  • Exhibit 10: Global peptide therapeutics market segmentation by drug class
  • Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology
  • Exhibit 12: Global peptide therapeutics market segmentation by geography 2015
  • Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions)
  • Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 18: Impact of drivers
  • Exhibit 19: Impact of drivers and challenges
  • Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions)
  • Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions)
  • Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions)
  • Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions)
  • Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions)
  • Exhibit 25: Eli Lilly: Key takeaways
  • Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions)
  • Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014
  • Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions)
  • Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014
  • Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions)
  • Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014
  • Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions)
  • Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014
  • Exhibit 34: Novo Nordisk: Key takeaways
  • Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions)
  • Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions)
  • Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions)
  • Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions)
  • Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions)
  • Exhibit 40: Sanofi: Key takeaways
  • Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions)
  • Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions)
  • Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions)
  • Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions)
  • Exhibit 45: Takeda Pharmaceutical: Key takeaways
  • Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
  • Exhibit 47: Teva Pharmaceuticals: Key takeaways
Back to Top